Señales en vivo de MXC.AX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 abr 2024 @ 01:10):

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines...

Stats
Volumen de hoy	47 232.00
Volumen promedio	23 177.00
Capitalización de mercado	18.42M
EPS	$0 ( 2024-02-25 )
Próxima fecha de ganancias	( $0 ) 2024-07-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0240 (5.78%)

Volumen Correlación

Largo: -0.04 (neutral)

Corto: 0.36 (neutral)

Signal:(47.63) Neutral

MGC Pharmaceuticals Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MGC Pharmaceuticals Ltd Correlación - Moneda/Commodity

-0.36
( neutral )

-0.42
( neutral )

0.00
( neutral )

0.05
( neutral )

0.41
( neutral )

MGC Pharmaceuticals Ltd Finanzas

Annual	2023
Ingresos:	$3.39M
Beneficio Bruto:	$698 740 (20.63 %)
EPS:	$-7.07

FY	2023
Ingresos:	$3.39M
Beneficio Bruto:	$698 740 (20.63 %)
EPS:	$-7.07

FY	2022
Ingresos:	$4.73M
Beneficio Bruto:	$1.56M (33.01 %)
EPS:	$-7.93

FY	2021
Ingresos:	$2.96M
Beneficio Bruto:	$1.31M (44.23 %)
EPS:	$-0.0115

Financial Reports:

No articles found.

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.